BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3532 related articles for article (PubMed ID: 23235682)

  • 1. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Zhou H; Han W; Zhang S
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009130. PubMed ID: 22161445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimethyl fumarate for multiple sclerosis.
    Xu Z; Zhang F; Sun F; Gu K; Dong S; He D
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
    Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
    Tramacere I; Del Giovane C; Salanti G; D'Amico R; Filippini G
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD011381. PubMed ID: 26384035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclizumab for relapsing remitting multiple sclerosis.
    Liu J; Wang LN; Zhan S; Xia Y
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
    Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod for relapsing-remitting multiple sclerosis.
    La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siponimod for multiple sclerosis.
    Cao L; Li M; Yao L; Yan P; Wang X; Yang Z; Lao Y; Li H; Yang K; Li K
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013647. PubMed ID: 34783010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 177.